Advertisement

AIDS and Behavior

, Volume 23, Issue 7, pp 1925–1938 | Cite as

Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP)

  • B. E. MeyersonEmail author
  • P. C. DinhJr
  • J. D. Agley
  • B. J. Hill
  • D. N. Motley
  • G. A. Carter
  • W. Jayawardene
  • P. T. Ryder
Original Paper

Abstract

To identify factors associated with pharmacist dispensing practice and comfort counseling patients about pre-exposure prophylaxis for HIV prevention (PrEP). Cross-sectional 2016 census of Indiana managing pharmacists measured PrEP awareness, comfort dispensing and counseling patients. Modified Poisson models with robust error variance estimated relative risks and confidence intervals. 15.8% of 284 pharmacists had dispensed PrEP and 11.6% had consulted about it. Dispensing and comfort counseling were associated with confidence in knowledge about PrEP medication adherence and adverse effects of PrEP medication; awareness about PrEP before the survey, number of full time pharmacists in their pharmacy, and increases in new HIV cases from 2015 to 2016 in communities served. Comfort counseling about PrEP was associated with the belief that pharmacists can be an important resource for HIV and HCV treatment.

Keywords

PrEP HIV prevention Pharmacy practice Pharmacist 

Resumen

Identificar los factores asociados con la práctica de dispensación de farmacéuticos y aconsejar a los pacientes sobre la profilaxis previa a la exposición para la prevención del VIH (PrEP). El censo transversal de 2016 de los farmacéuticos de Indiana midió el conocimiento de PrEP, la dispensación de la comodidad y el asesoramiento a los pacientes. Los modelos de Poisson modificados con una varianza de error robusta estimaron los riesgos relativos y los intervalos de confianza. El 15.8% de los 284 farmacéuticos habían dispensado PrEP y el 11.6% había consultado al respecto. El asesoramiento sobre la dispensación y la comodidad se asociaron con la confianza en el conocimiento sobre la adherencia a la medicación con PrEP y los efectos adversos de la medicación con PrEP; conocimiento sobre PrEP antes de la encuesta, número de farmacéuticos a tiempo completo en su farmacia, y aumentos en nuevos casos de VIH desde 2015 hasta 2016 en las comunidades atendidas. El asesoramiento de comodidad sobre la PrEP se asoció con la creencia de que los farmacéuticos pueden ser un recurso importante para el tratamiento del VIH y el VHC.

Notes

Funding

This study was funded in part by the Indiana Clinical and Translational Sciences Institute by Award Number UL1TR001108 from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. It was also funded in part by the Indiana University School of Public Health-Bloomington Faculty Research Grant Program.

Compliance with Ethical Standards

Conflict of interest

The authors have no conflicts of interest to disclose.

Research Involving Human Participants

This study was deemed exempt by the Indiana University IRB. Informed consent was obtained from all individuals participating in the study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Baeten J, Celum C. Oral antiretroviral chemoprophylaxis: current status. Curr Opin HIV AIDS. 2012;7(6):514–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PLoS ONE. 2013;8(5):e64038.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jayakumaran JS, Aaron E, Gracely EJ, Schriver E, Szep Z. Knowledge, attitudes, and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS ONE. 2016;11(2):e0145670.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Strauss BB, Greene GJ, Phillips G, Bhatia R, Madkins K, Parsons JT, Mustanski B. Exploring patterns of awareness and use of HIV pre-exposure prophylaxis among young men who have sex with men. AIDS Behav. 2017;21(5):1288–98.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ross I, Mejia C, Melendez J, Chan PA, Nunn AC, Powderly W, Goodenberger K, Liu J, Mayer KH, Patel RR. Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: implications for country-wide implementation. PLoS ONE. 2017;12(3):e0173057.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Smith DK, Mendoza MCB, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009-2015. PLoS ONE. 2016;11(6):e0156592.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18(2):226–40.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Norman J. Americans rate healthcare providers high on honesty, ethics. Social & Policy Issues 2016; December. http://news.gallup.com/poll/200057/americans-rate-healthcare-providers-high-honesty-ethics.aspx. Accessed 22 May 22 2018.
  11. 11.
    Bruno C, Saberi P. Pharmacists as providers of HIV pre-exposure prophylaxis. Int J Clin Pharm. 2012;34(6):803–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Moffat C, Matyanga J. The role of the pharmacist in pre-exposure prophylaxis. Pharmacol Pharm. 2014;5:225–8.CrossRefGoogle Scholar
  13. 13.
    Shaeer KM, Sherman EM, Shafiq S, Hardigan P. Exploratory survey of Florida pharmacists’ experience, knowledge and perceptions of HIV pre-exposure prophylaxis. Am J Pharm Assoc. 2014;54(6):610–7.CrossRefGoogle Scholar
  14. 14.
    Hammett TM, Phan S, Gaggin J, Case P, Zaller N, Lutnick A, Kral AH, Fedorova EV, Heimer R, Small W, Pollini R, Beletsky L, Latkin C, de Jarlais DC. Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies and barriers in six countries. BMC Health Serv Res. 2014;14(261):1–11.Google Scholar
  15. 15.
    Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc. 2003;2006(46):168–79.Google Scholar
  16. 16.
    Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDS. 2012;26:526–31.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Meyerson BE, Ryder PT, Richey-Smith C. Achieving pharmacy-based public health: a call for public health engagement. Public Health Rep. 2013;128:140–3.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bunting BA, Smith BH, Sutherland SE. The Ashville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2003;2008(48):23–31.Google Scholar
  19. 19.
    Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2003;2006(46):370–7.Google Scholar
  20. 20.
    Meyerson BE, Agley JD, Davis A, Jayawardene W, Hoss A, Shannon DJ, Ryder PT, Ritchie K, Gassman R. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana. Drug Alcohol Dependence. 2018.  https://doi.org/10.1016/j.drugalcdep.2018.03.032.CrossRefPubMedGoogle Scholar
  21. 21.
    Meyerson BE, Davis A, Agley JD, Shannon DJ, Lawrence CA, Ryder PT, Ritchie K, Gassman R. Predicting pharmacy syringe sales to people who inject drugs: policy practice and perceptions 2018. Int J Drug Policy. 2018;56:46–53.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Meyerson BE, Ryder PT, Von Hippel C, Coy K. We can do more than just sell the test: pharmacist perspectives about over the counter rapid HIV tests. AIDS Behav. 2013;17(6):2109–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Ryder PT, Meyerson BE, Coy KC, von Hippel CD. Pharmacists’ perspectives on HIV testing in community pharmacies. J Am Pharm Assoc. 2013;53:595–600.CrossRefGoogle Scholar
  24. 24.
    Amesty S, Blaney S, Crawford ND, Rivera AV, Fuller C. Pharmacy staff characteristics associated with support for pharmacy based HIV testing. AIDS Patient Care STDs. 2012;26(9):526–31.CrossRefGoogle Scholar
  25. 25.
    Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prevent Policy. 2015;10(1):1–10.CrossRefGoogle Scholar
  27. 27.
    Carter GA, Jayawardene W, Agley J, Garcia J, Miller W, Sherwood-Laughlin, C, Meyerson BE. Development of a 10-item tool to identify APN readiness to prescribe pre-exposure prophylaxis. (in review).Google Scholar
  28. 28.
    Matyanga CMJ, Khoza S, Gavi S. HIV pre-exposure prophylaxis: pharmacists knowledge, perception and willingness to adopt future implementation in a Zimbabwean urban setting. East Cent Afr J Pharm Sci. 2014;17(1):3–9.Google Scholar
  29. 29.
    Atkinson J, Sánchez Pozo A, Rekkas D, Volmer D, Hirvonen J, Bozic B, Skowron A, Mircioiu C, Sandulovici R, et al. Hospital and community pharmacists’ perceptions of which competencies are important for their practice. Pharm (Basel). 2016;4(2):21.PubMedCentralGoogle Scholar
  30. 30.
    Nash RE, Chalmers L, Stupans I, Brown N. Knowledge, use and perceived relevance of a profession’s Competency Standards; implications for Pharmacy Education. Int J Pharm Pract. 2016;24(6):390–402.CrossRefPubMedGoogle Scholar
  31. 31.
    Unni EJ, Lian N, Kuykendall W. Understanding community pharmacist perceptions and knowledge about HIV preexposure prophylaxis (PrEP) therapy in a mountain west state. J Am Pharm Assoc. 2016;56:527–32.CrossRefGoogle Scholar
  32. 32.
    Yoong D, Naccarato M, Sharma M, Wilton J, Senn H, Tan DHS. Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. Int J STD AIDS. 2016;27(8):608–16.CrossRefPubMedGoogle Scholar
  33. 33.
    Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012;26(7):893–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Balaji AB, Bowles KE, Le BC, Paz-Bailey G. Oster AM for the NHBS Study Group. High HIV incidence and prevalence and associated factors among young MSM, 2008. AIDS. 2013;27(2):269–78.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Meyerson BE, Agley JD, Davis A, Jayawardene W, Hoss A, Shannon DJ, Ryder PT, Ritchie K, Gassman R. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana. Drug Alcohol Depend. 2016;188:187–92.CrossRefGoogle Scholar
  36. 36.
    Agley JD, Meyerson BE, Shannon DJ, Ryder PT, Ritchie K, Gassman R. Using the hybrid method to survey U.S. pharmacists: applying lessons learned to leverage technology. Res Soc Adm Pharm. 2016;13:250–2.CrossRefGoogle Scholar
  37. 37.
    US Department of Agriculture Economic Research Service. Rural-Urban Commuting Area Codes. [online]: https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx Accessed 15 Sept 15 2016.
  38. 38.
    Health Resources and Services Administration. Medically Underserved Areas. https://bhw.hrsa.gov/shortage-designation/muap. Accessed 1 Sept 2016.
  39. 39.
    Patrick R, Forrest D, Cardenas G, Opoku J, Magnus M, Phillips G, Greenberg A, Metsch L, Kharfen M, et al. Awareness, willingness, and use of pre-exposure prophylaxis among men who have sex with men in Washington, DC and Miami Dade County, FL: National behavioral surveillance, 2011 and 2014. J Acquir Immune Defic Syndr. 2017;75(Supp 3):S375–82.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, Jones J, Castel A, Yeung H, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.CrossRefGoogle Scholar
  42. 42.
    Tabachnick BG, Fidell LS. Using multivariate statistics. 6th ed. Boston: Pearson Education; 2013.Google Scholar
  43. 43.
    Keeter S, Kennedy C, Dimock M, Best J, Craighill P. Gauging the Impact of Growing Nonresponse on Estimates from a National RDD Telephone Survey. Public Opin Q. 2006;70:759–79.CrossRefGoogle Scholar
  44. 44.
    Stuart GS, Grimes DA. Social desirability bias in family planning studies: a neglected problem. Contraception. 2009;80(2):108–12.CrossRefPubMedGoogle Scholar
  45. 45.
    Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, Haubrich R. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns and barriers to adoption of pre-exposure prophylaxis for HIV prevention among gay and bisexual men in HIV sero-discordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single young men who have sex with men in the United States. Curr HIV Res. 2013;11(7):520–7.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Eades CE, O’Carroll RE. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11:582.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Anderson C, Blenkinsopp A, Armstrong M. Feedback from community pharmacy users on the contribution of community pharmacy to improving the public’s health: a systemic review of the peer reviewed a non-peer reviewed literature 1990-2002. Health Expect. 2004;7(3):191–202.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006;46:370–7.CrossRefGoogle Scholar
  51. 51.
    Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. J Am Pharm Assoc. 2010;50:181–7.CrossRefGoogle Scholar
  52. 52.
    Letassy N, Dennis V, Lyons TJ, Harrison D, Burton M, Kirkpatrick A. Know your diabetes risk project: student pharmacists educating adults about diabetes risk in a community pharmacy setting. J Am Pharm Assoc. 2010;50:188–94.CrossRefGoogle Scholar
  53. 53.
    Patwardhan PD, Chewning BA. Effectiveness of intervention to implement tobacco cessation counseling in community chain pharmacies. J Am Pharm Assoc. 2012;52:507–14.CrossRefGoogle Scholar
  54. 54.
    Brown TJ, Todd A, O’Malley C, et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open. 2016;6:e009828.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Hayes Directories, Inc. Hayes Database of Retail Pharmacies. Mission Viejo, California. List published and purchased by authors December 2015.Google Scholar
  56. 56.
    Sheff JT, Nowak C, Maxey H. 2012 Indiana Pharmacist Workforce. Department of Family Medicine, Indiana University Purdue University at Indianapolis. https://scholarworks.iupui.edu/bitstream/handle/1805/6479/2012%20Indiana%20Pharmacist%20Workforce.pdf;sequence=1. Accessed 14 Nov 2018.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Indiana University School of Public Health-BloomingtonBloomingtonUSA
  2. 2.Rural Center for AIDS/STD PreventionIndiana UniversityBloomingtonUSA
  3. 3.Indiana Prevention Research CenterIndiana UniversityBloomingtonUSA
  4. 4.Institute for Research on Addictive BehaviorIndiana UniversityBloomingtonUSA
  5. 5.Center for Interdisciplinary Inquiry and Innovation in Sexual and Reproductive Health (Ci3)The University of ChicagoChicagoUSA
  6. 6.Indiana University School of NursingBloomingtonUSA
  7. 7.Larkin University College of PharmacyMiamiUSA
  8. 8.Planned Parenthood Great PlainsOverland ParkUSA

Personalised recommendations